Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules

Abstract

PurposeThis study aimed to evaluate the safety, tolerability and pharmacokinetics of the combination of oral vinorelbine with erlotinib using the conventional (CSV) and metronomic (MSV) dosing schedules in patients with advanced non-small cell lung cancer (NSCLC).MethodsThis was an open-label, multiple dose-escalation phase I study. An alternating 3+3 phase I design was employed to allow each schedule to enroll three patients sequentially at each dose level. Thirty patients with Stage IIIB/IV NSCLC were treated with escalating doses of oral vinorelbine starting at 40 mg/m2 on day 1 and 8 in the CSV group (N = 16) and at 100 mg/week in the MSV group (N = 14). Erlotinib was administered orally daily.ResultsThe maximum tolerated dose was vinorelbine 80 mg/m2 with erlotinib 100 mg in the CSV group and vinorelbine 120 mg/week with erlotinib 100 mg in the MSV group. Grade 3/4 toxicities included neutropenia (N = 2; 13%) and hyponatremia (N = 1; 6%) in the CSV group, and neutropenia (N = 5; 36%) in the MSV group. Objective response was achieved in 38% and 29% in the CSV and MSV groups respectively. Vinorelbine co-administration did not significantly affect the pharmacokinetics of erlotinib and OSI-420 after initial dose. However, at steady-state, significantly higher Cmax, higher Cmin and lower CL/F of erlotinib were observed with increasing dose levels of vinorelbine in the CSV group. Significantly higher steady-state Cmin, Cavg and AUCss of erlotinib were observed with increasing dose levels of vinorelbine in the MSV group.ConclusionsCombination of oral vinorelbine with erlotinib is feasible and tolerable in both the CSV and MSV groups.Trial RegistrationClinicalTrials.gov NCT00702182

A Phase I Comparative Pharmacokinetic and Safety Study of Two Intravenous Formulations of Vinorelbine in Patients With Advanced Non-Small Cell Lung Cancer

“…formulation are warranted. Overall, our results are consistent with previous safety data and show no new safety signal (Marty et al, 2001; Hirsh et al, 2007; Briasoulis et al, 2013; Sutiman et al, 2016; Bilir et al, 2017; Kaburaki et al, 2017).…”

Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation

“… 3 – 5 Erlotinib in treatment of various solid tumors such as non-small-cell lung cancer is available in oral form. 6 , 7 Oral bioavailability of erlotinib in healthy volunteers and cancer patients was 59% and 76%, respectively. 8 , 9 There are no data on other forms of such drugs.…”

Metronomic chemotherapy in non‑small cell lung cancer (Review)

“…Oral vinorelbine and erlotinib. Sutiman et al (40) designed a phase I study of oral vinorelbine in combination with erlotinib using conventional (CSV) and metronomic (MSV) dosing schedules in NSCLC to evaluate the safety, tolerability and pharmacokinetics of treatments. Oral vinorelbine 40 mg/m 2 in the CSV group (n=16) and 100 mg/week in the MSV group (n=14) was administered on days 1 and 8.…”